Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts

Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts

Source: 
Fierce Pharma
snippet: 

In March, the Federal Trade Commission (FTC) under newly elected President Joe Biden announced a major review of how it has handled mergers and acquisitions in pharma and biotech. Not surprisingly, the news prompted some Wall Street analysts and legal experts to fret that the increased political scrutiny—fueled by ongoing concerns about drug pricing—could put the kibosh on M&A in the industry.

Those worries seem to have been unfounded.